March 11, 2026

Introducing RaDaR^® ST

We’re excited to introduce the latest from our team of passionate innovators and precision oncology pioneers who have been working tirelessly to develop a molecular residual disease (MRD) test you can rely on to monitor recurrence in your HPV-negative head and neck cancer and HR+/HER2- breast cancer patients. GET TO KNOW RaDaR ST How does it work? RaDaR ST analyzes each patient's unique tumor profile to develop a personalized panel—then uses that panel to detect the presence or absence of circulating tumor DNA in the patient's bloodstream. Why RaDaR ST for MRD testing?   RaDaR ST delivers:   Proven performance with clinical evidence Personalized MRD detection for every patient   Detection as low as 1ppm* Clear reporting for confident decision making   Broad in-network payor contracts Seamless ordering workflows   To learn more about why you should add RaDaR ST to your oncology toolset, visit our website. *Sensitivity demonstrated across four independent analytical and clinical validation studies, with detection down to 1 part per million (ppm) under study-specific conditions. Data on file.

Introducing PD-L1 22C3 FDA for Ovarian Carcinoma

PD-L1 22C3 FDA for Ovarian Carcinoma is now available to support precision oncology in ovarian cancer patients. This advanced immunohistochemistry (IHC) assay empowers clinicians to support patients with recurrent ovarian cancer who may benefit from a new targeted therapy. This advanced immunohistochemistry (IHC) assay detects PD-L1 protein expression in ovarian carcinoma and is performed in accordance with manufacturer specifications, utilizing the FDA-approved PD-L1 IHC 22C3 pharmDx. The assay utilizes the 22C3 clone with Combined Positive Score (CPS) assessment and integrates into established laboratory workflows. Testing is available: As a standalone PD-L1 companion diagnostic assay As part of the NeoTYPE Ovarian Tumor Profile, which consolidates HER2, FOLR1, and PD-L1 testing within a single ovarian biomarker framework. NeoTYPE Ovarian Tumor Profile previously included PD-L1 LDT, our new PD-L1 22C3 FDA for Ovarian Carcinoma replaces the LDT in this profile. For cases requiring broader molecular insights, PanTracer Pro may be utilized to complement IHC-based biomarker evaluation through comprehensive genomic profiling (CGP). Ordering information: Rapid Turnaround Time: Global: 2 days, Tech-Only: 1 day Level of Service: Global and Tech-Only CPT Code*: 88360x1 NYS Approved: Yes Updated test requisition forms are available. As a trusted leader in oncology diagnostics, NeoGenomics has delivered reliable PD-L1 testing for years, understanding its critical role in guiding treatment strategies. With this FDA-approved companion diagnostic, we’re reinforcing our commitment to delivering high-quality, actionable results that drive informed decision-making and improve patient outcomes. *The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

Expanded MPN NGS Testing available in New York state

Myeloproliferative neoplasm (MPN) next-generation sequencing (NGS) testing is now available in New York state. This expansion delivers enhanced analytical sensitivity, broader exon coverage for the JAK2 gene, and a faster turnaround time of 7 days or less for all tests, empowering you with more comprehensive and timely results for patient care.  The following MPN NGS assays are now fully validated and available in New York state: MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12–15, CALR, and MPL JAK2 V617F Mutation Analysis by NGS JAK2 Extended (Exon 12–15 nonV617F) Mutation Analysis by NGS CALR Mutation Analysis by NGS MPL Mutation Analysis by NGS Important: You can now find these tests in the NeoTYPE/NextGen Sequencing section of NeoLINK when placing an online order. The NGS assays will replace the current tests that are performed by PCR, bi-directional sequencing and/or fragment length analysis (FLA). Orders of the old tests will be automatically accessioned for the new tests. Our expanded test menu supports more accurate and efficient detection of clinically actionable mutations, helping guide diagnosis, prognosis, and therapeutic decisions with confidence.  Learn  more. Additionally, please visit  our website to learn our services, call our  dedicated Client Services team at 866.776.5903, option 3, or email us at Client.Services@NeoGenomics.com.  Interface Clients: This test update will involve changes to test names and codes. Please refer to the Interface Updates section for more info.

Better AML Patient Outcomes Are Possible with Express - Now Available in New York State

NeoGenomics’ new AML Express panel supports better outcomes for acute myeloid leukemia (AML) patients with rapid and detailed genetic insights to guide treatment decisions. Its comprehensive NGS-based assessment delivers rapid diagnostic, predictive, or therapeutic information to make informed, personalized treatment decisions. Ensure that your patients receive the most current and effective treatments. Learn more about AML Express.

NGS Testing for Patients with Myeloid Disorders

Guidelines recommend next-generation sequencing (NGS) at diagnosis for precise risk stratification, emphasizing its superior diagnostic value and cost-effectiveness compared to single-gene testing.1     Comprehensive NGS testing at diagnosis changes everything for myeloid patients:    Detects 74% more actionable biomarkers   Boosts targeted therapy use by 12%   Cuts non-targeted chemo by 40%2     Neo  Comprehensive® – Myeloid Disorders, a  CGP assay, uses DNA and RNA NGS to detect relevant aberrations for diagnostic  evaluation, prognosis, risk stratification, and therapy guidance for a wide  range of myeloid disorders.  1. Levine RL, Valk PJM. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica. 2019 May;104(5):868-871. doi: 10.3324/haematol.2018.205955. Epub 2019 Mar 28. PMID: 30923100; PMCID: PMC6518900. 2. Rosenquist R, Bernard E, Erkers T, et al. Novel precision medicine approaches and treatment strategies in hematological malignancies. J Intern Med. 2023;294(4):413-436.   Neo  Comprehensive® – Myeloid Disorders, a  CGP assay, uses DNA and RNA NGS to detect relevant aberrations for diagnostic  evaluation, prognosis, risk stratification, and therapy guidance for a wide  range of myeloid disorders.  1. Levine RL, Valk PJM. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica. 2019 May;104(5):868-871. doi: 10.3324/haematol.2018.205955. Epub 2019 Mar 28. PMID: 30923100; PMCID: PMC6518900. 2. Rosenquist R, Bernard E, Erkers T, et al. Novel precision medicine approaches and treatment strategies in hematological malignancies. J Intern Med. 2023;294(4):413-436.

c-MET CDx for NSCLC IHC

We’ve added the c-MET CDx for NSCLC IHC assay to our comprehensive NSCLC test offerings, and it can now be included with PanTracer™ Tissue orders to support broad biomarker analysis in lung cancer. Explore the impact HGFR (MET) testing can have on your lung cancer practice by visiting our website. For a complete list of recent test updates, click here for a downloadable document to view the impacted interface test codes.